References
- Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin. 2009;25:2429–2438.
- Kunz M. Current treatment of psoriasis with biologics. Curr Drug Discov Technol. 2009;6:231–240.
- Hankin CS, Feldman SR, Szczotka A, Stinger RC, Fish L, Hankin DL. A cost comparison of treatments of moderate to severe psoriasis. Drug Benefit Trends. 2005;17:200–214.
- Nelson AA, Pearce DJ, Fleischer AB Jr, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008;58:125–135.
- Beyer V, Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010;146:46–54.
- Enbrel [package insert]. Thousand Oaks, CA: Immunex; 2009.
- Stelara [package insert]. Horsham, PA: Centocor Ortho Biotech Inc.; 2009.
- Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118–128.
- Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman WR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat. 2010 May 5 [Epub ahead of print].
- Poulin Y, Langley RG, Teixeira HD, Martel MJ, Cheung S. Biologics in the treatment of psoriasis: Clinical and economic overview. J Cutan Med Surg. 2009;13(suppl 2):S49–57.
- Fredriksson T, Pettersson U. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978;157:238–244.
- NICE technology appraisal guidance 180. Ustekinumab for the treatment of adults with moderate to severe psoriasis. London: National Institute for Health and Clinical Excellence; 2009.
- Ustekinumab, 45 mg solution for injection (Stelara®). Report No. (572/09). Scottish Medicines Consortium; 2010 February 8. Available from: http://www.scottishmedicines.org.uk/files/ustekinumab_Stelara_FINAL_January_2010_Amended_04.02.10_for_website.pdf.
- Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–1674.
- Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, For the Etanercept Psoriasis Study Group. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–2022.
- Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–1684.
- Analysource Online. 2010 July 7. Available from: http://www.analysource.com/.
- National Health and Nutrition Examination Survey Data. Hyatsville, MD: Centers for Disease Control and Prevention (CDC) and National Center for Health Statistics (NCHS); 2003.
- Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. Curr Med Res Opin. 2008;24:3493–3501.
- Lebwohl M. Psoriasis. Lancet. 2003;361:1197–1204.
- Wu Y, Mills D, Bala M. Impact of psoriasis on patients' work and productivity: A retrospective, matched case–control analysis. Am J Clin Dermatol. 2009;10:407–410.
- Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213:102–110.